Immunologic Research

, Volume 36, Issue 1, pp 137–146

Helper roles of NK and CD8+ T cells in the induction of tumor immunity

Polarized dendritic cells as cancer vaccines

Authors

  • Pawel Kalinski
    • Department of SurgeryUniversity of Pittsburgh
    • Department of ImmunologyUniversity of Pittsburgh
    • Department of Infectious Diseases and MicrobiologyUniversity of Pittsburgh
    • Department of SurgeryUniversity of Pittsburgh Cancer Institute, Hillman Cancer Center, Res. Pavilion
  • Yutaro Nakamura
    • Department of SurgeryUniversity of Pittsburgh
  • Payal Watchmaker
    • Department of SurgeryUniversity of Pittsburgh
  • Adam Giermasz
    • Department of SurgeryUniversity of Pittsburgh
  • Ravikumar Muthuswamy
    • Department of SurgeryUniversity of Pittsburgh
  • Robbie B. Mailliard
    • Department of SurgeryUniversity of Pittsburgh
Article

DOI: 10.1385/IR:36:1:137

Cite this article as:
Kalinski, P., Nakamura, Y., Watchmaker, P. et al. Immunol Res (2006) 36: 137. doi:10.1385/IR:36:1:137

Abstract

The work in our laboratory addresses two interrelated areas of dendritic cell (DC) biology: (1) the role of DCs as mediators of feedback interactions between NK cells, CD8+ and CD4+ T cells; and (2) the possibility to use such feedback and the paradigms derived from anti-viral responses, to promote the induction of therapeutic immunity against cancer. We observed that CD8+ T cells and NK cells, the classical “effector” cells, also play “helper” roles, regulating ability of DCs to induce type-1 immune immunity, critical for fighting tumors and intracellular pathogens. Our work aims to delineate which pathways of NK and CD8+ T cell activation result in their helper activity, and to identify the molecular mechanisms allowing them to induce type-1 polarized DCs (DC1s) with selectively enhanced ability to promote type-1 responses and anti-cancer immunity. The results of these studies allowed us and our colleagues to design phase I/II clinical trials incorporating the paradigms of DC polarization and helper activity of effector cells in cancer immunotherapy.

Key Words

Dendric cellsCancerImmunotherapyVaccinesTh 1CTLNK cellsClinical trialsMelanomaColorectal cancerProstate cancer

Copyright information

© Humana Press Inc. 2006